- $2.14bn
- $1.86bn
- $445.76m
- 85
- 33
- 74
- 69
Annual cashflow statement for Veracyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -34.9 | -75.6 | -36.6 | -74.4 | 24.1 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 17.7 | 26.4 | 34.4 | 99.4 | 49.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.481 | 4.22 | -16.4 | -4.16 | -21.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -9.71 | -31.6 | 7.54 | 44.2 | 75.1 |
| Capital Expenditures | -2.84 | -5.38 | -8.55 | -9.96 | -11.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1 | -734 | -20.8 | 25.1 | -45 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -3.84 | -739 | -29.4 | 15.1 | -56.3 |
| Financing Cash Flow Items | -3.85 | -9.03 | -3.17 | -6.74 | -15.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 204 | 596 | 3.49 | 2.84 | 4.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 190 | -176 | -18.9 | 62.3 | 23.3 |